- Home
- CULP vs COEP Comparison
CULP vs COEP Comparison
Compare CULP & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CULP | COEP |
|---|---|---|
| Founded | 1972 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.7M | 100.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CULP | COEP |
|---|---|---|
| Price | $3.78 | $15.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 20.7K | ★ 72.9K |
| Earning Date | 12-10-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $207,391,000.00 | $500,996.00 |
| Revenue This Year | $1.93 | N/A |
| Revenue Next Year | $2.77 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.42 | $2.31 |
| 52 Week High | $5.94 | $21.41 |
Technical Indicators
Market Signals| Indicator | CULP | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 41.41 | 46.35 |
| Support Level | $3.78 | $15.40 |
| Resistance Level | $3.95 | $16.80 |
| Average True Range (ATR) | 0.13 | 1.48 |
| MACD | 0.00 | -0.17 |
| Stochastic Oscillator | 16.05 | 6.60 |
Price Performance
Historical ComparisonAbout CULP Culp Inc.
Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.